Long-term outcome of patients after a single interruption of antiretroviral therapy: A cohort study

BMC Research Notes

Volumn 5, Issue , 2012, Pages

  Machado, Carmen ^a   Ríos Villegas, María José ^a,b   Gálvez Acebal, Juan ^a,b   Domínguez Castellano, Angel ^a,b   Fernández Cuenca, Felipe ^a   Palomo, Virginia ^a   Muniain, Miguel Angel ^a,b   Rodríguez Baño, Jesús ^a,b  

^a HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^b UNIVERSITY OF SEVILLE   (Spain)

Author keywords

Antiretroviral therapy; Cohort study; HIV 1; Outcome; Treatment interruption

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; DRUG ADMINISTRATION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MIDDLE AGED; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84867663557     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-5-578     Document Type: Article

References (19)

1. Starting highly active antiretroviral therapy: why, when and response to HAART. Mocroft A, Lundgren JD, J Antimicrob Chemother 2004 54 10 13 10.1093/jac/dkh290 15163656
2. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 2011 1 167 Disponible en: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Consultado el 11/12/2011
3. European AIDS Clinical Society (EACS). Guidelines, version 6.1. 2011 Disponible en: http://www.europeanaidsclinicalsociety.org/images/stories/EACS- Pdf/eacsguidelines-v6-english.pdf. Consultado el 11/12/2011
4. Documento de consenso de Gesida/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el VIH (Actualización 01.2011). Panel de expertos de GESIDA y Plan Nacional sobre el Sida, Enferm Infecc Microbiol Clin 2011 29 1 e103 Disponible en: http://www.gesida.seimc.org/pcientifica/fuentes/DcyRc/gesidadcyrc2011- Documentoconsenso-TAR-adulto-verimprimir.pdf. Consultado el 11/12/2011 21419527
5. Structured treatment interruptions (STI) in chronic suppressed HIV infection in adults. Pai NP, Tulsky JP, Lawrence J, Colford JM, Reingold AL, Cochrane Database Syst Rev 2005 4 D005482 16235406
6. CD4+ guided antiretroviral treatment interruption in HIV infection: a meta-analysis. Seminari E, De Silvestri A, Boschi A, Tinelli C, AIDS rev 2008 10 236 244 19092979
7. Impact of different patterns of nonadherence on the outcome of highly active antiretroviral therapy in patients with long-term follow-up. Knobel H, Urbina O, González A, Sorlí ML, Montero M, Carmona A, et al. HIV Med 2009 10 364 369 10.1111/j.1468-1293.2009.00696.x 19490179
8. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Center for Diseases Control and Prevention (CDC), MMWR Morb Mortal Wkly Rep 1992 41 RR-17 1 19 1364245
9. Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years - United States, 2008. Schneider E, Whitmore S, Glynn KM, Dominguez K, Mitsch A, McKenna MT, Centers for Disease Control and Prevention (CDC), MMWR Recomm Rep 2008 57 RR-10 1 12 19052530
10. Managing antiretroviral therapy: changing regimens, resistance testing, and the risks from structured treatment interruptions. Eron JJ, Journal Infectious Diseases 2008 197 Suppl. 3 261 271
11. Validation of a simplified adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA Study. Knobel H, Alonso J, Casado JL, Collazos J, González J, Ruiz I, et al. AIDS 2002 16 605 613 10.1097/00002030- 200203080-00012 11873004
12. CD4 cell-guided scheduled treatment interruptions in HIV-infected patients with sustained immunologic response to HAART. Maggiolo F, Airoldi M, Callegaro A, et al. AIDS 2009 23 799 807 19114869
13. Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170. Skiest DJ, Su Z, Havlir DV, Robertson KR, Coombs RW, Cain P, et al. J Infect Dis 2007 195 1426 1436 10.1086/512681 17436222
14. Interrupción del tratamiento antirretroviral en pacientes con infección crónica por el virus de la inmunodeficiencia humana. Amador C, Pasquau F, Ena J, de Apodaca RF BCyR, Med Clin 2005 125 41 45 10.1157/13076461
15. Discontinuation of antiretroviral therapy in patients with chronic HIV infection: clinical, virologic, and immunological consequences. Mata RC, Viciana P, De Alarcon A, et al. AIDS Patient Care and STDs 2005 19 6 18
16. Factores que predicen el fracaso de las interrupciones del tratamiento antirretroviral (TAR) en los pacientes con infección por el VIH. Cervero-Jiménez M, Torres-Perea R, Ruiz-Capillas JJ, Álamo M, Agud JL, Solís J, et al. Enferm Infecc Microbiol Clin 2005 23 202 207 10.1157/13073145 15826544
17. Enchanced risk of HIV sexual transmission during structured treatment interruption. Teicher E, Casagrande T, Vittecoq D, Sex Trans Infect 2003 79 74 10.1136/sti.79.1.74
18. Antiretroviral therapy interruptions guided by CD4 cell count and plasma HIV-1 RNA levels in chronically HIV-1 infected patients. Ruiz L, Paredes R, Gómez G, Romeu J, Domingo P, Pérez-Alvarez N, et al. AIDS 2007 21 169 178 10.1097/QAD.0b013e328011033a 17197807
19. Risk of selecting de novo drug-resistance mutations during structured treatment interruptions in pacients with chronic HIV infection. Arnedo-Valero M, García F, Gil C, Guila T, Fumero E, Castro P, et al. Clin Infect Dis 2005 41 883 890 10.1086/432881 16107990